Vienna, Austria
Vienna, Austria
SEARCH FILTERS
Time filter
Source Type

News Article | May 22, 2017
Site: www.businesswire.com

PARIGI--(BUSINESS WIRE)--Sofinnova Partners, società europea leader in venture capital, specializzata nel settore delle bioscienze, ha nominato Graziano Seghezzi Managing Partner. La nomina di Seghezzi, che nel suo nuovo ruolo va ad affiancare Antoine Papiernik, Denis Lucquin e Monique Saulnier, contribuisce a incrementare la leadership sui mercati internazionali di Sofinnova Partners e a consolidare la strategia di crescita finalizzata a rafforzare, in tutta Europa, il suo ruolo primario nel settore degli investimenti per le bioscienze. Nei prossimi anni, Sofinnova Partners incrementerà le sue attività attraverso team appositamente dedicati e investimenti mirati. Attiva sul mercato italiano da oltre 15 anni, con più di 50 milioni di euro investiti in aziende del settore Biotech, Sofinnova Partners considera quello italiano un mercato strategico per il prossimo futuro caratterizzato da opportunità di investimento fra le più promettenti in Europa. Graziano Seghezzi ha iniziato la sua carriera nel venture Capital nel 2001 a Sofinnova Partners col compito di identificare e valutare nuove opportunità di investimento. Nel corso della sua carriera si è dedicato alla creazione di imprese attraverso l’implementazione di start-up, spin-off e acceleratori. È stato investitore principale di Omthera Pharmaceuticals, società che si è quotata al NASDAQ e successivamente venduta ad Astra Zeneca, di Glycovaxyn poi venduta a GSK e di Creabilis venduta a Sienna Biopharmaceuticals. È stato investitore ed è tuttora nel Consiglio di Amministrazione di Breath Therapeutics, Corvidia Therapeutics, Crescendo Biologics, Hookipa Biotech, Inotrem and Mission Therapeutics. Graziano Seghezzi è anche fra i co-fondatori di BiovelocITA, il primo acceleratore italiano dedicato alle aziende biotech. Dal 2003 al 2006 ha lavorato presso Index Venture di Ginevra. Nei precedenti cinque anni, aveva lavorato come ricercatore alla New York University, School of Medicine, operando nel campo oncologico e delle malattie cardiovascolari. Ha una laurea in genetica e microbiologia ottenuta presso la Università di Pavia e un MBA presso l’Università RSM-Erasmus (Olanda). “Nutro una grande stima per la squadra di Sofinnova Partners a livello professionale ma anche dal punto di vista personale. Sono dunque particolarmente felice di questo mio nuovo ruolo di Managing Partner che arriva in un momento fondamentale per la società che ha elaborato un’ambiziosa strategia di crescita. Sono pronto a mettere in campo tutta la mia pluriennale esperienza internazionale per contribuire attivamente all’ulteriore sviluppo, a livello globale della leadership, di Sofinnova Partners nel campo delle bioscienze.” afferma Graziano Seghezzi Antoine Papiernik, Presidente di Sofinnova Partners sottolinea: ”Graziano entrò in Sofinnova Partners 15 anni fa, dando una svolta alla sua carriera e trasformandosi da ricercatore accademico a investitore del biotech. In questo periodo ha messo a segno investimenti davvero importanti sia in Europa sia negli Stati Uniti. È un piacere dargli il benvenuto nel novero dei Managing Partner di questa società” Sofinnova Partners Sofinnova Partners è una società di venture capital europea, leader del settore e specializzata nelle bioscienze, con sede a Parigi. L’attenzione della società è focalizzata su modelli tecnologici ad alto contenuto innovativo e su imprenditori visionari. L’obiettivo della società è di operare come socio fondatore e investitore principale in start-up e in spin-off d’impresa. In oltre 40 anni, Sofinnova Partners ha promosso e finanziato quasi 500 società creando leader di mercato mondiali. Oggi Sofinnova Partners ha un volume totale di fondi in gestione superiore a 1,6 miliardi di euro. (www.sofinnova.fr)


News Article | May 22, 2017
Site: www.businesswire.com

C’est en 2001 que Graziano a démarré sa carrière dans le capital-risque chez Sofinnova Partners où il est chargé de trouver et analyser les nouvelles opportunités d’investissement. Tout au long de son parcours, il s’est engagé pour promouvoir la création d’entreprises, à la fois par des créations de start up, mais aussi par la réalisation de spin-offs et la mise en place d’accélérateurs. Il a été l’investisseur de démarrage d’Omthera Pharmaceuticals, initialement cotée sur le Nasdaq puis vendu à Astra Zeneca, de Glycovaxyn, vendu à GSK, et de Creabilis vendu à Sienna Biopharmaceuticals. Il a également investi et siège au conseil d’administration de Breath Therapeutics, Corvidia Therapeutics, Crescendo Biologics, Hookipa Biotech, Inotrem et Mission Therapeutics. Il a co-fondé BioVelocita, le premier accélérateur italien. Entre 2003 et 2006, Graziano travaille chez Index Ventures à Genève. Scientifique de formation, il a passé cinq ans comme chercheur médical, spécialisé dans l’oncologie et les maladies cardiovasculaires, à l’Ecole de Médecine de NYU (Etats Unis). Graziano est diplômé de l’Université de Pavia (Italie) en génétique et microbiologie et détient un MBA de RSM Erasmus University. A propos de Sofinnova Partners Sofinnova Partners est un des leaders du capital risque en Europe spécialisé dans les sciences de la vie. Basée à Paris, la société investit dans les technologies de changement de paradigme aux côtés d’entrepreneurs visionnaires. Sofinnova Partners intervient en priorité dans les start up et spin-off d’entreprises en tant qu’investisseur fondateur et chef de file. Depuis plus de 45 ans, la société a accompagné plus de 500 entreprises à travers le monde devenues des leaders sur leur marché. Sofinnova Partners gère aujourd’hui 1,6 milliard d’euros. Pour plus d’information : www.sofinnova.fr


News Article | May 22, 2017
Site: www.businesswire.com

Graziano Seghezzi startete seine Karriere im Jahr 2001 im Risikokapitalbereich bei Sofinnova Partners, wo er für die Identifizierung und Bewertung von Investitionsmöglichkeiten zuständig zeichnete. Im Verlauf seiner Karriere konzentrierte er sich auf Unternehmensgründungen durch die Förderung von Startups, Unternehmensausgliederungen und Entwicklungsbeschleunigern. Er war Seed-Investor bei dem an der Nasdaq notierten und später von Astra Zeneca übernommenen Unternehmen Omthera Pharmaceuticals, bei dem an die GSK verkauften Unternehmen Glycovaxyn und bei dem von Sienna Biopharmaceuticals übernommenen Unternehmen Creabilis. Er investierte in Breath Therapeutics und war zudem Mitglied dessen Board of Breath Therapeutics. Darüber hinaus investierte er in die Unternehmen Corvidia Therapeutics, Crescendo Biologics, Hookipa Biotech, Inotrem und Mission Therapeutics. Graziano Seghezzi war schließlich auch Mitbegründer von BiovelocITA, dem ersten Beschleuniger des Biotechnologiesektors in Italien. Zwischen 2003 und 2006 arbeitete er für Index Ventures in Genf. Als ausgebildeter Wissenschaftler arbeitete Graziano Seghezzi fünf Jahre lang in der wissenschaftlichen Forschung an der NYU School of Medicine (USA), wo er in den Bereichen Onkologie und Herz-Kreislauf-Erkrankungen tätig war. Er erwarb einen Abschluss in Genetik und Mikrobiologie an der Universität Pavia (Italien) und einen MBA an der RSM-Erasmus Universität (Niederlande). Antoine Papiernik, Chairman von Sofinnova Partners ergänzte: „Graziano Seghezzi trat vor 15 Jahren in das Unternehmen Sofinnova Partners ein, als er einen Karrierewechsel von der wissenschaftlichen Forschung zu einem Investor im Biotechnologiesektor vollzog. Heute verfügt er als Investor über eine außerordentliche Erfolgsbilanz in Europa und den Vereinigten Staaten. Wir sind daher hocherfreut, ihn nun in unserem Managing Partnership Team begrüßen zu können." Über Sofinnova Partners Sofinnova Partners ist ein europaweit führendes Risikokapitalunternehmen, das sich auf Biowissenschaften spezialisiert hat. Mit Sitz in Paris, Frankreich, konzentriert sich das Unternehmen auf bahnbrechende Technologien neben visionären Unternehmern. Sofinnova Partners ist bestrebt, als Gründungs- und Leadinvestor in Startups und Unternehemnsausgliederungen zu investieren, und hat knapp 500 Unternehmen in über 40 Ländern unterstützt und Marktführer rund um den Globus geschaffen. Sofinnova Partners verwaltet heute über 1,6 Milliarden Euro. Weitere Informationen finden Sie unter www.sofinnova.fr


News Article | May 22, 2017
Site: www.businesswire.com

PARIS--(BUSINESS WIRE)--Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, has appointed Graziano Seghezzi as Managing Partner. He joins Antoine Papiernik, Denis Lucquin, and Monique Saulnier in the company’s Managing Partnership. Graziano’s appointment boosts Sofinnova Partners’ international leadership. Graziano began his career in venture capital in 2001 at Sofinnova Partners where he was in charge of identifying and assessing investment opportunities. Throughout his career, he has focused on company creation through the establishment of start ups, spin-offs, and accelerators. He was the seed investor of Omthera Pharmaceuticals, listed on Nasdaq and then sold to Astra Zeneca, of Glycovaxyn sold to GSK and of Creabilis sold to Sienna Biopharmaceuticals. He also invested and is on the Board of Breath Therapeutics, Corvidia Therapeutics, Crescendo Biologics, Hookipa Biotech, Inotrem and Mission Therapeutics. Graziano also co-founded BiovelocITA, Italy’s first biotech accelerator. Between 2003 and 2006, he worked at Index Ventures in Geneva. A scientist by training, Graziano spent five years working in academic research at NYU School of Medicine (USA), studying oncology and cardiovascular diseases. He holds a degree in genetics and microbiology from the University of Pavia (Italy) and an MBA from RSM-Erasmus University (Netherlands). Graziano Seghezzi says: « I have tremendous respect for the Sofinnova team both on a professional and on a personal level; I am therefore particularly happy to be promoted Managing Partner. This new role comes at a pivotal moment for the partnership which has devised an ambitious growth strategy. With my extensive international expertise, I am looking forward to actively contribute to further develop Sofinnova Partners’ global leadership in Life Sciences ». Antoine Papiernik, Chairman of Sofinnova Partners adds: « Graziano came to Sofinnova Partners fifteen years ago, as he was changing careers from academic researcher to biotech investor. Today, he has built a true investment track record both in Europe and in the United States; we are very pleased to welcome him to the Managing Partnership ». About Sofinnova Partners Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs, and has backed nearly 500 companies over more than 40 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.6 billion under management. For more information, please visit: www.sofinnova.fr


News Article | November 28, 2016
Site: www.newsmaker.com.au

The report provides comprehensive information on the therapeutics under development for Cytomegalovirus (HHV-5) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections   and features dormant and discontinued projects. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Complete report on Cytomegalovirus (HHV-5) Infections - Pipeline Review, H2 2016 addition with 53 market data tables and 16 figures, spread across 177 pages is available at http://www.reportsnreports.com/reports/764557-cytomegalovirus-hhv-5-infections-pipeline-review-h2-2016.html This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, Investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis Adicet Bio, Inc.,AIMM Therapeutics BV,Astellas Pharma Inc,Atara Biotherapeutics Inc,AvidBiotics Corp,Biotest AG ,Chimerix Inc ,China Biologic Products Inc,CyTuVax BV ,Fate Therapeutics Inc,GlaxoSmithKline Plc,Hookipa Biotech AG,Kadmon Corp LLC,Laboratoires Thea SA,Merck & Co Inc ,Microbiotix Inc ,Mymetics Corp ,Novartis AG ,Pfizer Inc ,Phoenix Biotechnology Inc,Savoy Pharmaceuticals, Inc.,Sigma-Tau SpA ,Themis Bioscience GmbH Inquire before buying http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=764557premium report price at US$2000 for a single user PDF license).


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2011.1.4-4 | Award Amount: 40.88M | Year: 2011

Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and powerful immunization technologies for the next generation of human vaccines. This goal requires a multidisciplinary approach in which diverse but complementary scientific disciplines and technologies converge. Therefore some of the most competitive European research groups from public institutions and biotechs have agreed to join forces in ADITEC, together with top US groups on systems biology and adjuvants to support this enterprise. A systems biology approach will be used to study licensed and experimental vaccines in patient characterization studies and in clinical trials, to investigate the effect of adjuvants, vectors, formulations, delivery devices, routes of immunization, homologous and heterologous primeboost schedules, as well as the impact of host factors such as age, gender, genetics and pathologies. Animal models will be used to complement human studies, and to select novel immunization technologies to be advanced to the clinic. To address these issues in a coordinated manner, ADITEC is organised on a matrix structure in which research themes and experimental approaches feed into each other. Training curricula will be created to impact on the formation of the next generation of EU researchers in the field. ADITEC scientists and institutions are part of the Sclavo Vaccines Association (SVA), which is dedicated to vaccines and vaccine research. SVA, acting as the coordinating institution, guarantees the long-term commitment and sustainability of this initiative, beyond the duration of ADITEC itself.


News Article | December 14, 2016
Site: www.marketwired.com

ATLANTA, GA--(Marketwired - Dec 14, 2016) -  GeoVax Labs, Inc. ( : GOVX), a biotechnology company specializing in developing human vaccines, announced today that Farshad Guirakhoo, PhD, has been promoted to the role of Chief Scientific Officer, effective January 1, 2017. Dr. Guirakhoo joined GeoVax in 2015 as Senior Vice President of Research and Development. Robert T. McNally, PhD, GeoVax's President and Chief Executive Officer, commented, "For the past year, Farshad has been a driving force behind the growth of our vaccine development pipeline, and we are pleased to expand his role at this critical time for our company. In the role of Chief Scientific Officer, Dr. Guirakhoo will lead the scientific advancement of GeoVax's technology pipeline as the Company identifies and pursues new opportunities to address significant medical needs." Dr. McNally continued, "Harriet Robinson, PhD, will continue to hold an instrumental position with GeoVax as Chief Scientific Officer Emeritus. In this role, she will continue to direct our HIV vaccine program as well as continuing to serve as principal investigator on grants to GeoVax from the National Institutes of Health. Dr. Robinson, a co-founder of GeoVax, will also continue to serve as a member of our Board of Directors." Before joining GeoVax in 2015, Dr. Guirakhoo served in senior management and scientific roles within the biotechnology industry with Vaxess Technologies, Hookipa Biotech, Sanofi Pasteur, Acambis, Inc. and OraVax, Inc. He earned his Ph.D. in Virology at the Medical University of Vienna, Vienna, Austria, holds a M.Sc. degree in Genetics and a B.Sc. degree in Biology. He conducted his Post-Doctoral training at the Medical University of Vienna and at the US National Centers for Disease Control and Prevention (CDC), Division of Vector-Borne Infectious Diseases in Fort Collins, CO. In his scientific career, Dr. Guirakhoo has filed over 90 patent applications and is author/co-author of more than 80 peer reviewed publications, including book chapters. He was instrumental in the development and commercialization of the Imojev Japanese encephalitis virus vaccine and the Dengvaxia vaccine for Dengue virus. In 2014, he was named as one of the 50 Most Influential People in Vaccines. About GeoVax GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) vaccine platform. The Company's development programs are focused on vaccines against HIV, Zika, and hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa). GeoVax recently began programs to evaluate the use of its MVA-VLP platform in cancer immunotherapy and for therapeutic use in chronic Hepatitis B infections. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com.


Monath T.P.,Hookipa Biotech | Monath T.P.,Paxvax, Inc. | Vasconcelos P.F.C.,Instituto Evandro Chagas | Vasconcelos P.F.C.,National Institute of Science and Technology for Viral Hemorrhagic Fevers | Vasconcelos P.F.C.,Pará State University
Journal of Clinical Virology | Year: 2015

Yellow fever, a mosquito-borne flavivirus disease occurs in tropical areas of South America and Africa. It is a disease of major historical importance, but remains a threat to travelers to and residents of endemic areas despite the availability of an effective vaccine for nearly 70 years. An important aspect is the receptivity of many non-endemic areas to introduction and spread of yellow fever. This paper reviews the clinical aspects, pathogenesis, and epidemiology of yellow fever, with an emphasis on recent changes in the distribution and incidence of the disease. Recent knowledge about yellow fever 17D vaccine mechanism of action and safety are discussed. © 2014 Elsevier B.V.

Loading Hookipa Biotech collaborators
Loading Hookipa Biotech collaborators